SCHEMBL1463079

SCHEMBL1463079

O=C(OCC12CC3CC(CC(C3)C1)C2)OS(=O)(=O)C(F)(F)S(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
P2RX7 Q99572 5/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
SCN9A Q15858 2/20 0.37
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
MEN1 O00255 3/20 0.35
ENPP3 O14638 1/20 0.35
CA2 P00918 1/20 0.35
ENPP1 P22413 1/20 0.35
ENPP2 Q13822 1/20 0.35
CA9 Q16790 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26191695 0.79 EPHX2 (0.41) KMT2AP2RX7ALDH1A1MEN1EPHX2
SCHEMBL28975360 0.78 SCN9A (0.35) KMT2ANPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL961708 0.75 KMT2A (0.37) KMT2ANPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL26191707 0.74 EPHX2 (0.36) KMT2ANPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL1079673 0.73 P2RX7 (0.39) KMT2ANPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL6449720 0.72 GAA (0.41) KMT2ASMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL977611 0.72 P2RX7 (0.36) KMT2ANPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL3024913 0.71 GAA (0.38) KMT2ASMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL28975361 0.70 SCN9A (0.36) ALDH1A1SCN9AL3MBTL1
SCHEMBL961481 0.69 ALDH1A1 (0.35) KMT2ANPC1RAB9ASMN1; SMN2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580486-B2 Salt having fluorine-containing carbanion structure, derivative thereof, photoacid generator, resist material using the photoacid generator, and pattern forming method CENTRAL GLASS COMPANY, LIMITED (JP) 2013-11-12 US disclosed
US-20110070544-A1 Novel Salt Having Fluorine-Containing Carbanion Structure, Derivative Thereof, Photoacid Generator, Resist Material Using the Photoacid Generator, and Pattern Forming Method Central Glass Company,Ltd. (JP) 2011-03-24 US disclosed
EP-2264007-A1 NOVEL SALT HAVING FLUORINE-CONTAINING CARBANION STRUCTURE, DERIVATIVE THEREOF, PHOTOACID GENERATOR, RESIST MATERIAL USING THE PHOTOACID GENERATOR, AND PATTERN FORMING METHOD Central Glass Company, Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070544-A1 Novel Salt Having Fluorine-Containing Carbanion Structure, Derivative Thereof, Photoacid Generator, Resist Material Using the Photoacid Generator, and Pattern Forming Method ARF1, ARF5, ARF6 KMT2A 1129/4885NPC1 2473/4885RAB9A 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.